Idiopathic pulmonary fibrosis
The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).
Treatment with nintedanib and pirfenidone can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, section 85 for a patient with IPF.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing nintedanib and pirfenidone.
Make all initial applications for authority approval to prescribe nintedanib or pirfenidone for the treatment of IPF in writing and either:
All applications must include the completed:
- authority prescription form(s)
- Idiopathic pulmonary fibrosis Initial PBS authority application form
- relevant attachments.
To make continuing applications for treatment with with nintedanib or pirfenidone call the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for more information.
Page last updated: 1 November 2019
This information was printed 10 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/idiopathic-pulmonary-fibrosis. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.